
Monthly PVX108 Raises Peanut Tolerance in Children, With Brian Vickery, MD
Key Takeaways
- AVX-201 randomized 71 children across 14 US/Australia sites to PVX108 5 nmol, 50 nmol, or placebo for 12 months with oral food challenge–based maximum tolerated dose as primary endpoint.
- Clinically, 50 nmol yielded higher responder rates (39.4% tolerating ≥443 mg cumulative peanut protein) versus placebo (16.7%), approaching coverage for typical accidental exposures (~100–150 mg).
Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.
Once-monthly intradermal PVX108, a T-cell epitope peptide immunotherapy, increased the maximum tolerated peanut dose vs placebo in children aged 4 to 11 years with
The randomized, double-blind, placebo-controlled AVX-201 trial enrolled 71 children across 14 sites in the US and Australia and compared 5 nmol and 50 nmol doses with placebo over 12 months.² The 50 nmol group showed a 2.4-fold increase in maximum tolerated dose from baseline vs a 1.2-fold increase with placebo.² At month 12, 39.4% of participants receiving 50 nmol tolerated a cumulative dose of at least 443 mg of peanut protein, compared with 16.7% receiving placebo.²
No treatment-related allergic adverse events, anaphylaxis, or treatment-related serious adverse events occurred at either dose, according to the company.² A follow-up food challenge after a 6-month treatment-free period showed maintenance or improvement in clinical effects at month 18, and 59 of 68 completers (87%) entered a 12-month open-label extension.² PVX108 holds FDA Fast Track designation for the treatment of peanut allergy.²
In the following Q&A, Brian P. Vickery, MD, chief of allergy and immunology at Children’s Healthcare of Atlanta and professor and vice-chair of pediatric clinical research at Emory University School of Medicine, discusses the dose findings, the peptide approach to safety, the durability of effect of treatment, and what phase 3 will need to show.
Q&A: Monthly PVX108 Raises Peanut Tolerance in Children
HCPLive: The primary endpoint compared the maximum tolerated dose of peanut protein at food challenge before and after treatment. What did you see, and how should clinicians read that change in terms of protection from accidental exposure in daily life?
Brian P. Vickery, MD: The primary efficacy endpoint showed that, after 1 year of treatment, children in the 50 nmol group were able to significantly increase the amount of peanut protein tolerated during an oral food challenge by 2.4-fold, compared to the amount tolerated during a pre-treatment oral food challenge. In another analysis, 39% of these participants were able to tolerate ≥ 300 mg of peanut protein during the post-treatment challenge. This could be enough of a change to protect some of these participants from accidental peanut exposures, which average between 100 - 150 mg.
HCPLive: The trial tested 2 dose levels in children. How did the 5 nmol and 50 nmol doses compare, and what does that tell you about where the dose should land for phase 3?
Brian P. Vickery, MD: The 50 nmol dose outperformed the 5 nmol dose, which is unlikely to be further developed.
HCPLive: PVX108 is built from T-cell epitope peptides rather than whole peanut protein. How does that change the safety profile during treatment, and what did you see for reactions, including injection-site events?
Brian P. Vickery, MD: PVX108 consists of 7 synthetic peptide fragments, which are designed to interact with the T cells that orchestrate allergic inflammation while being too small to interact with IgE. Therefore, PVX108 should not trigger acute allergic reactions, unlike other forms of immunotherapy using intact allergens. Consistent with this, there were no treatment-related allergic reactions or anaphylaxis seen in this study or in the previously published phase 1 study in peanut-allergic adults.
HCPLive: The study includes an off-treatment period. What do the data so far suggest about whether the effect lasts after dosing stops, and why does that matter for the idea of disease modification?
Brian P. Vickery, MD: All participants were treated for 12 months and then treatment was stopped following the post-treatment oral food challenges. Then participants abstained from further treatment for 6 months and returned to the research unit for follow-up challenges at month 18 to determine if any of the treatment benefit was sustained. Over half of the month 12 responders sustained or even improved their challenge performance at month 18, which suggests the potential for long-term benefit.
HCPLive: What questions does this phase 2 trial leave open, and what would you want a phase 3 trial to show before you’d feel ready to offer this to families?
Brian P. Vickery, MD: This study was small, with fewer than 25 participants in each arm, and used an appropriate statistical analysis strategy for small, early-stage studies. Going into phase 3, the study will be substantially larger and will need to replicate or even surpass the efficacy results seen here, while at the same time requiring a more robust statistical analysis.
HCPLive: Is there anything else about these findings, or about where peanut allergy immunotherapy is heading, that you want clinicians to know?
Brian P. Vickery, MD: PVX108 also lessened the severity of allergic symptoms during the post-treatment food challenge reactions and was associated with improvement in self-reported quality of life in participants aged 8-11 years, as reported by the FAQLQ-Child Form.
References
Vickery BP. Precision immunotherapy to treat peanut allergy: topline phase 2 results of PVX108 in children. Presented at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; November 14, 2026; Phoenix, AZ.
Aravax announces positive results of phase 2 clinical trial of PVX108, a novel immunotherapy for the treatment of peanut allergy. Aravax. Published November 12, 2026. Accessed November 20, 2026.
https://www.bioindustry.org/resource/aravax-announces-positive-results-of-phase-2-clinical-trial-of-pvx108--a-novel-immunotherapy-for-the-treatment-of-peanut-allergy.html
Related to this article








